Navigating evolving regulatory CMC guidance in the AAV gene therapy field
M Brewer, A Cockroft, C Fuentes et al
Driving the expansion of mRNA into the therapeutic sphere
Alejandro Becerra, Andreas Kuhn, Metin Kurtoglu
Regulatory requirements and product attributes for cGMP viral vector production
Scott Cross, Shikha Mishra
Manufacturing considerations underpinning viral & non-viral platform selection
A Hagerman, A Noyes, V Slepushkin et al
Successful suspension-based viral vector manufacturing scale-up from process development to clinic
D Kole, T P Cripe, L Giannunzio et al
Current technological trends & advancements in vector purification
Y Cai, N Clement, C Gaskin et al
Roundtable Roundup: strategies for scaling up and out in gene therapy manufacturing - addressing AAV’s growing pains
Christopher Reardon, Phillip Vermilion, John Yoshi Shyu
Abeona Therapeutics evaluates a scalable suspension-based platform for production of viral vector for MPS-IIIA
Anne MacIntyre, Phil Maples
Optimizing downstream purification of high-quality plasmid DNA with POROS™ Chromatography Resins
Alejandro Becerra, Johannes Buyel
Advances in AAV process development
Alejandro Becerra, Matthias Hebben, Michael Mercaldi
COVID-19 vaccine approvals: key lessons for mRNA therapeutics
V Indurthi, PhD, J Barberio, S Zobbi et al